The Max Foundation and Friends of Max Strengthen Partnership

Hyderabad, India–

The Max Foundation (Max) and Friends of Max (FOM) proudly announce the formalization of their long standing collaboration supporting people living with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) in India. The two organizations signed a landmark Memorandum of Understanding (MOU) at the recent Friends of Max 2015 Leadership Summit attended by Max CEO, Pat Garcia-Gonzalez in Hyderabad on April 19th.

Viji Venkatesh, Max’s Head of India shares an historical perspective, “In 2003, leaders of Max’s team in India and community leaders agreed to collaborate on providing free support services to families affected by CML and GIST in the country. This collaboration resulted in the formation of Friends of Max, a Charitable Trust registered with the Charities Commissioner’s Office in Mumbai. Today, we celebrate our MOU signing to enable greater support to people living with CML and GIST across the country.”

Pat Garcia-Gonzalez of Max remarks, “Since its inception, Friends of Max has served as the patient support arm of The Max Foundation. We are a united force. We are grateful for our partnership of so many years and full of hope as we look ahead to how much we can accomplish together.”

About Friends of Max
Friends of Max is a charitable trust registered in India comprised of individuals impacted directly and indirectly by chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). With 18 chapters in cities across India, the trust aims to provide mutual support and education for its thousands of active members under the motto, “Together we share and learn”.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….

  • Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

    Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

    The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a GIST patient meeting in Seattle, he has provided our program with invaluable training and support. “Dr. Wagner has gone above and beyond in advising our….

  • The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    Building on two decades of progress, Max’s ambitious goal will expand its proven, patient-centered model that has already helped more than 100,000 people access treatment Commitment will enhance local health system capabilities to deliver innovative and generic medicines, diagnostics, and treatment in more than 80 low- and middle-income countries Alongside this commitment, Max and Novartis sign….